Diagnostic performance of HPV E6/E7 mRNA testing towards HPV-DNA testing and p16/Ki67 immunostaining as a biomarker of high-risk HPV recurrence in Greek women surgically treated for their cervical lesions.
CIN treatment
E6/E7 HPV-mRNA overexpression
HPV-mRNA testing
cervical cancer
post-op surveillance
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
11
07
2021
received:
11
04
2021
accepted:
29
07
2021
pubmed:
11
8
2021
medline:
6
10
2021
entrez:
10
8
2021
Statut:
ppublish
Résumé
To evaluate the diagnostic performance of E6/E7 HPV-mRNA overexpression towards HPV-DNA testing and p16/Ki67 immunocytochemistry in a post-op population to verify if this biomarker can be effectively used as indicator of successful cervical intraepithelial neoplasia (CIN) treatment. Our study retrospectively analyzed 197 patients of our Colposcopy Clinic between January 2013 and September 2020 coming with an abnormal Pap smear suggestive for colposcopy, and after a series of follow-ups including liquid-based cytology (LBC) and punch-biopsy sampling, there were surgically treated. LBC was used for cytology and molecular analysis of the three HPV-related biomarkers. Six months after treatment, 93% of the HPV-mRNA-positive women became negative while this applied to only 80.2% of the HPV-DNA-positive women. HPV persistence was 6.9% at 6-12 months after treatment. The comparison among cytology, colposcopy, HPV-DNA test, and HPV-mRNA test after treatment revealed that the last one is the only with a strong correlation with actual severity (histology during treatment) (ρ = 0.345, p = 0.006) implying that clinical cases with more severe CIN may have higher chances of unsuccessful treatment. HPV-mRNA test had higher sensitivity (100%), specificity (96.88%), and positive predictive value (45.45%) for CIN2+ recurrent lesions when compared with HPV-DNA testing (80%, 82.81%, 10.81% respectively) and p16/Ki67 immunocytochemistry (80%, 95.83%, 33.33% respectively) while their negative predictive values were similar. E6/E7 mRNA detection has higher diagnostic values for the prediction of treatment failure compared with HPV-DNA testing and p16/Ki67 immunocytochemistry, and as an outcome could be used as predictive indicator of CIN-treatment status.
Substances chimiques
Ki-67 Antigen
0
Oncogene Proteins, Viral
0
RNA, Messenger
0
DNA
9007-49-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3607-3617Informations de copyright
© 2021 Japan Society of Obstetrics and Gynecology.
Références
Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147-72. https://doi.org/10.3322/caac.21139
Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group, Kyrgiou M, Kalliala I, Mitra A, Fotopoulou C, Ghaem-Maghami S, et al. Immediate referral to colposcopy versus cytological surveillance for minor cervical cytological abnormalities in the absence of HPV test. Cochrane Database Syst Rev. 2020;2020:CD009836. https://doi.org/10.1002/14651858.CD009836.pub2
Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12-9. https://doi.org/10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
Bosch FX, Lorincz A, Muñoz N, Meijer CJLM, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-65. https://doi.org/10.1136/jcp.55.4.244
Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16:1-17. https://doi.org/10.1128/CMR.16.1.1-17.2003
Kyrgiou M, Tsoumpou I, Vrekoussis T, Martin-Hirsch P, Arbyn M, Prendiville W, et al. The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy & cervical cytopathology collaborative group (C5 group) approach. Cancer Treat Rev. 2006;32:516-23. https://doi.org/10.1016/j.ctrv.2006.07.008
Chen J-Y, Wang Z-L, Wang Z-Y, Yang X-S. The risk factors of residual lesions and recurrence of the high-grade cervical intraepithelial lesions (HSIL) patients with positive-margin after conization. Medicine (Baltimore). 2018;97:e12792. https://doi.org/10.1097/MD.0000000000012792
Lili E, Chatzistamatiou K, Kalpaktsidou-Vakiani A, Moysiadis T, Agorastos T. Low recurrence rate of high-grade cervical intraepithelial neoplasia after successful excision and routine colposcopy during follow-up. Medicine (Baltimore). 2018;97:e9719. https://doi.org/10.1097/MD.0000000000009719
Li L, Chen C-X, Jiang Y-M. Meta-analysis of cold-knife conization versus loop electrosurgical excision procedure for cervical intraepithelial neoplasia. Onco Targets Ther. 2016;9:3907-15. https://doi.org/10.2147/OTT.S108832
Kocken M, Helmerhorst TJM, Berkhof J, Louwers JA, Nobbenhuis MAE, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol. 2011;12:441-50. https://doi.org/10.1016/S1470-2045(11)70078-X
Kalliala I, Anttila A, Pukkala E, Nieminen P. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ. 2005;331:1183-5. https://doi.org/10.1136/bmj.38663.459039.7C
Soutter WP, de Barros Lopes A, Fletcher A, Monaghan JM, Duncan ID, Paraskevaidis E, et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet. 1997;349:978-80. http://www.ncbi.nlm.nih.gov/pubmed/9100623
Strander B, Hallgren J, Sparen P. Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. BMJ. 2014;348:f7361. https://doi.org/10.1136/bmj.f7361
Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer. 2006;118:2048-55. https://doi.org/10.1002/ijc.21604
Mariani L, Sandri MT, Preti M, Origoni M, Costa S, Cristoforoni P, et al. HPV-testing in follow-up of patients treated for CIN2+ lesions. J Cancer. 2016;7:107-14. https://doi.org/10.7150/jca.13503
Alonso I, Torné A, Puig-Tintoré LM, Esteve R, Quinto L, Campo E, et al. Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2-3. Gynecol Oncol. 2006;103:631-6. https://doi.org/10.1016/j.ygyno.2006.04.016
Bigrigg A, Haffenden DK, Sheehan AL, Codling BW, Read MD. Efficacy and safety of large-loop excision of the transformation zone. Lancet. 1994;343:32-4. http://www.ncbi.nlm.nih.gov/pubmed/7905048
Thompson AD, Duggan MA, Nation J, Brasher PMA. Investigation of laser cervical cone biopsies negative for premalignancy or malignancy. J Low Genit Tract Dis. 2002;6:84-91. http://www.ncbi.nlm.nih.gov/pubmed/17051006
Carrigg A, Teschendorf C, Amaro D, Weidner N, Tipps A, Shabaik A, et al. Examination of sources of diagnostic error leading to cervical cone biopsies with no evidence of dysplasia. Am J Clin Pathol. 2013;139:422-7. https://doi.org/10.1309/AJCP6BSD0SNGQLHQ
Verguts J, Bronselaer B, Donders G, Arbyn M, van Eldere J, Drijkoningen M, et al. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. BJOG. 2006;113:1303-7. https://doi.org/10.1111/j.1471-0528.2006.01063.x
Moarcăs M, Georgescu IC, Brătilă E, Badea M, Cîrstoiu M. Clinical significance of HPV-DNA testing for precancerous cervical lesions. J Med Life. 2014;7:37-9. http://www.ncbi.nlm.nih.gov/pubmed/25870692
Gao G, Smith DI. Human papillomavirus and the development of different cancers. Cytogenet Genome Res. 2016;150:185-93. https://doi.org/10.1159/000458166
Louvanto K, Rintala MA, Syrjänen KJ, Grénman SE, Syrjänen SM. Incident cervical infections with high- and low-risk human papillomavirus (HPV) infections among mothers in the prospective Finnish Family HPV Study. BMC Infect Dis. 2011;11:179. https://doi.org/10.1186/1471-2334-11-179
Mills AM, Dirks DC, Poulter MD, Mills SE, Stoler MH. HR-HPV E6/E7 mRNA in situ hybridization. Validation against PCR, DNA in situ hybridization, and p16 immunohistochemistry in 102 samples of cervical, vulvar, anal, and head and neck neoplasia. Am J Surg Pathol. 2017;41:607-15. https://doi.org/10.1097/PAS.0000000000000800
Carcea F, Daniilidis A, Vavoulidis E, Nasioutziki M, Papanikolaou A, Dinas K. A cohort retrospective study of high-risk HPV recurrence in Greek women after cervical lesion treatment through detection of viral E6/E7 mRNA expression. JBUON. 2020;25:99-107.
Nayar R, Wilbur D. The Bethesda system for reporting cervical cytology - definitions, criteria, and explanatory notes. 3rd ed. Switzerland: Springer International Publishing; 2015.
Stasinou SM, Valasoulis G, Kyrgiou M, Malamou-Mitsi V, Bilirakis E, Pappa L, et al. Large loop excision of the transformation zone and cervical intraepithelial neoplasia: a 22-year experience. Anticancer Res. 2012;32:4141-5. http://www.ncbi.nlm.nih.gov/pubmed/22993375
Wentzensen N, Schwartz L, Zuna RE, Smith K, Mathews C, Gold MA, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res. 2012;18:4154-62. https://doi.org/10.1158/1078-0432.CCR-12-0270
Nasioutziki M, Daniilidis A, Dinas K, Kyrgiou M, Valasoulis G, Loufopoulos PD, et al. The evaluation of p16INK4a immunoexpression/immunostaining and human papillomavirus DNA test in cervical liquid-based cytological samples. Int J Gynecol Cancer. 2011;21:79-85. https://doi.org/10.1097/IGC.0b013e3182009eea
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34. https://doi.org/10.3322/caac.21551
Dafni U, Tsourti Z, Alatsathianos I. Breast cancer statistics in the European Union: incidence and survival across European countries. Breast Care. 2019;14:344-53. https://doi.org/10.1159/000503219
Gyllensten U, Gustavsson I, Lindell M, Wilander E. Primary high-risk HPV screening for cervical cancer in post-menopausal women. Gynecol Oncol. 2012;125:343-5. https://doi.org/10.1016/j.ygyno.2012.01.036
Varnai AD, Bollmann M, Bankfalvi A, Speich N, Schmitt C, Griefingholt H, et al. Predictive testing of early cervical pre-cancer by detecting human papillomavirus E6/E7 mRNA in cervical cytologies up to high-grade squamous intraepithelial lesions: diagnostic and prognostic implications. Oncol Rep. 2008;19:457-65. https://doi.org/10.3892/or.19.2.457
Argyri E, Tsimplaki E, Daskalopoulou D, Stravopodis DJ, Kouikoglou O, Terzakis E, et al. E6/E7 mRNA expression of high-risk HPV types in 849 Greek women. Anticancer Res. 2013;33:4007-11.
Hoffman SR, Le T, Lockhart A, Sanusi A, Dal Santo L, Davis M, et al. Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): a systematic review. Int J Cancer. 2017;141:8-23. https://doi.org/10.1002/ijc.30623
Mesher D, Szarewski A, Cadman L, Cubie H, Kitchener H, Luesley D, et al. Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer. 2010;102:1405-10. https://doi.org/10.1038/sj.bjc.6605619
Onuki M, Matsumoto K, Sakurai M, Ochi H, Minaguchi T, Satoh T, et al. Posttreatment human papillomavirus testing for residual or recurrent high-grade cervical intraepithelial neoplasia: a pooled analysis. J Gynecol Oncol. 2016;27:e3. https://doi.org/10.3802/jgo.2016.27.e3
Heymans J, Benoy IH, Poppe W, Depuydt CE. Type-specific HPV geno-typing improves detection of recurrent high-grade cervical neoplasia after conisation. Int J Cancer. 2011;129:903-9. https://doi.org/10.1002/ijc.25745
van der Heijden E, Lopes AD, Bryant A, Bekkers R, Galaal K. Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): impact of human papillomavirus (HPV) test. Cochrane Database Syst Rev. 2015;1:CD010757. https://doi.org/10.1002/14651858.CD010757.pub2
Formana D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30:F12-23. https://doi.org/10.1016/j.vaccine.2012.07.055
Zappacosta R, Ianieri MM, Tinelli A, Gustapane S, D'angelo C, Gatta DM, et al. Detection of residual/recurrent cervical disease after successful LEEP conization: the possible role of mRNA-HPV test. Curr Pharm Des. 2013;19:1450-7. http://www.ncbi.nlm.nih.gov/pubmed/23016778
Frega A, Sesti F, Lombardi D, Votano S, Sopracordevole F, Catalano A, et al. Assessment of HPV-mRNA test to predict recurrent disease in patients previously treated for CIN 2/3. J Clin Virol. 2014;60:39-43. https://doi.org/10.1016/j.jcv.2014.01.017
Tropé A, Jonassen CM, Sjøborg KD, Nygård M, Dahl FA, Alfsen GC, et al. Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia. Gynecol Oncol. 2011;123:257-62. https://doi.org/10.1016/j.ygyno.2011.07.032
Macedo ACL, da Luz Moretti Borba C, Bavaresco DV, Colonetti T, Grande AJ, da Rosa MI. Accuracy of mRNA HPV tests as a predictor of recurrence of precursor lesions and cervical cancer after conization: a systematic review and meta-analysis. Biomark Med. 2019;13:497-506. https://doi.org/10.2217/bmm-2018-0373
Valasoulis G, Koliopoulos G, Founta C, Kyrgiou M, Tsoumpou I, Valari O, et al. Alterations in human papillomavirus-related biomarkers after treatment of cervical intraepithelial neoplasia. Gynecol Oncol. 2011;121:43-8. https://doi.org/10.1016/j.ygyno.2010.12.003
Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30:F55-70. https://doi.org/10.1016/j.vaccine.2012.06.083
Persson M, Wendel SB, Ljungblad L, Johansson B, Weiderpass E, Andersson S. High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia. Oncol Rep. 2012;28:346-52. https://doi.org/10.3892/or.2012.1755
Wheeler CM, Hunt WC, Cuzick J, Langsfeld E, Pearse A, Montoya GD, et al. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination. Int J Cancer. 2013;132:198-207. https://doi.org/10.1002/ijc.27608
Kang WD, Oh MJ, Kim SM, Nam JH, Park CS, Choi HS. Significance of human papillomavirus genotyping with high-grade cervical intraepithelial neoplasia treated by a loop electrosurgical excision procedure. Am J Obstet Gynecol. 2010;203:72.e1-6. https://doi.org/10.1016/j.ajog.2010.01.063
Rositch AF, Soeters HM, Offutt-Powell TN, Wheeler BS, Taylor SM, Smith JS. The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review. Gynecol Oncol. 2014;132:767-79. https://doi.org/10.1016/j.ygyno.2013.12.040
Zappacosta R, Gatta DMP, Marinucci P, Capanna S, Lattanzio G, Caraceni D, et al. Role of E6/E7 mRNA test in the diagnostic algorithm of HPV-positive patients showing ASCUS and LSIL: clinical and economic implications in a publicly financed healthcare system. Expert Rev Mol Diagn. 2015;15:137-50. https://doi.org/10.1586/14737159.2015.961915
Tropé A, Sjøborg K, Eskild A, Cuschieri K, Eriksen T, Thoresen S, et al. Performance of human papillomavirus DNA and mRNA testing strategies for women with and without cervical neoplasia. J Clin Microbiol. 2009;47:2458-64. https://doi.org/10.1128/JCM.01863-08
Castle PE, Dockter J, Giachetti C, Garcia FAR, McCormick MK, Mitchell AL, et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res. 2007;13:2599-605. https://doi.org/10.1158/1078-0432.CCR-06-2881
Kottaridi C, Tsiodras S, Spathis A, Chranioti A, Pappas A, Kassanos D, et al. Clinical performance of human papillomavirus E6, E7 mRNA flow cytometric assay compared to human papillomavirus DNA typing. Anal Quant Cytol Histol. 2011;33:305-10. http://www.ncbi.nlm.nih.gov/pubmed/22590807
Coquillard G, Palao B, Patterson BK. Quantification of intracellular HPV E6/E7 mRNA expression increases the specificity and positive predictive value of cervical cancer screening compared to HPV DNA. Gynecol Oncol. 2011;120:89-93. https://doi.org/10.1016/j.ygyno.2010.09.013
Kraus I, Molden T, Holm R, Lie AK, Karlsen F, Kristensen GB, et al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J Clin Microbiol. 2006;44:1310-7. https://doi.org/10.1128/JCM.44.4.1310-1317.2006
Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence? Implications for cervical disease progression and monitoring. J Med Virol. 2004;73:65-70. https://doi.org/10.1002/jmv.20062
Sauter JL, Mount SL, John TLS, Wojewoda CM, Bryant RJ, Leiman G. Testing of integrated human papillomavirus mRNA decreases colposcopy referrals: could a change in human papillomavirus detection methodology lead to more cost-effective patient care? Acta Cytol. 2014;58:162-6. https://doi.org/10.1159/000358246